A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancer

被引：0
|
作者：
Zhao, Weihong
Zhang, Zheng
Zhang, Yadi
Chen, Yimeng
Zhu, Yimin
Liu, Chuanling
Shao, Jiakang
Zhang, Li
Liu, Mei
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[2] Peoples Liberat Army Med Coll, Beijing, Peoples R China
[3] Nankai Univ, Sch Med, Tianjin, Peoples R China
[4] Xi An Jiao Tong Univ, Dept Med Oncol, Xian, Peoples R China
[5] Chinese Peoples Liberat Army, Gen Hosp, Med Ctr 5, Dept Med Oncol, Beijing, Peoples R China
[6] Chinese Peoples Liberat Army, Gen Hosp, Med Ctr 1, Dept Med Oncol, Beijing, Peoples R China
[7] Chinese Peoples Liberat Army, Gen Hosp, Med Ctr 6, Dept Pathol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13090
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancer
    Zhang, Zheng
    Zhang, Yadi
    Liu, Chuanling
    Shao, Jiakang
    Chen, Yimeng
    Zhu, Yimin
    Zhang, Li
    Qin, Boyu
    Kong, Ziqing
    Wang, Xixi
    Wang, Yutong
    Huang, Deqin
    Liu, Liqun
    Zhou, Yuxin
    Tao, Ran
    Yang, Zengjie
    Liu, Mei
    Zhao, Weihong
    CANCER INNOVATION, 2023, 2 (03): : 172 - 180
  • [2] The Evolving Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Steiner, Meghan
    Tan, Antoinette R.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (05) : 305 - 315
  • [3] Our experience with immune checkpoint inhibitors in triple-negative breast cancer patients
    Nishio, Minako
    Kojitani, Yoshiki
    Kitashiro, Saya
    Ishiduka, Yasunobu
    Otsuka, Tomoyuki
    Nishida, Naohiro
    Fujisawa, Fumie
    Sugimoto, Naotoshi
    Yagi, Toshinari
    Souma, Ai
    Kanaoka, Haruka
    Oyamayama, Yuri
    Taniguchi, Azusa
    Nakajima, Satomi
    Seto, Yukiko
    Kusama, Hiroki
    Watanabe, Noriyuki
    Matsui, Saki
    Nakayama, Takahiro
    Kudou, Toshihiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1465 - S1465
  • [4] Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer
    Quintana, A.
    Saini, K. S.
    Vidal, L.
    Peg, V.
    Slebe, F.
    Loibl, S.
    Curigliano, G.
    Schmid, P.
    Cortes, J.
    ESMO OPEN, 2024, 9 (10)
  • [5] The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
    Singh, Sima
    Numan, Arshid
    Maddiboyina, Balaji
    Arora, Saahil
    Riadi, Yassine
    Md, Shadab
    Alhakamy, Nabil A.
    Kesharwani, Prashant
    DRUG DISCOVERY TODAY, 2021, 26 (07) : 1721 - 1727
  • [6] Real-world outcomes of Black women versus non-Hispanic White women with advanced triple-negative breast cancer treated with immune checkpoint inhibitors at an urban cancer center.
    Aldrich, Jeffrey
    Switchenko, Jeffrey M.
    Kalinsky, Kevin
    Bhave, Manali A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China
    Chen, Yimeng
    Guan, Yin
    Wang, Jiayu
    Ma, Fei
    Luo, Yang
    Chen, Shanshan
    Zhang, Pin
    Li, Qing
    Cai, Ruigang
    Li, Qiao
    Mo, Hongnan
    Lan, Bo
    Chen, Xuelian
    Zhao, Weihong
    Xu, Binghe
    Fan, Ying
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (12) : 3490 - 3499
  • [8] Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
    Said, Sawsan Sudqi
    Ibrahim, Wisam Nabeel
    BIOMEDICINES, 2024, 12 (02)
  • [9] Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer
    Michel, Laura L.
    von Au, Alexandra
    Mavratzas, Athanasios
    Smetanay, Katharina
    Schuetz, Florian
    Schneeweiss, Andreas
    TARGETED ONCOLOGY, 2020, 15 (04) : 415 - 428
  • [10] Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer
    Laura L. Michel
    Alexandra von Au
    Athanasios Mavratzas
    Katharina Smetanay
    Florian Schütz
    Andreas Schneeweiss
    Targeted Oncology, 2020, 15 : 415 - 428
12345